Jennifer N. Brudno, M.D.
Dr. Brudno researches the use of chimeric antigen receptor (CAR) T-cell therapy to treat cancers of the blood, including Non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma. Her focus is in the development of phase I clinical trials. She is also interested in patient safety, particularly in optimizing patient safety for cellular immunotherapies.
1) Hodgkin and Non-Hodgkin lymphoma, 2) multiple myeloma, 3) chimeric antigen receptor (CAR) T-cell therapy, 4) toxicities of immunotherapy
Dr. Brudno conducts clinical trials to investigate new therapies for hematologic malignancies. Her focus is in the development and execution of clinical trials of chimeric antigen receptor (CAR) T-cell therapy.
Selected Key Publications
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.J Clin Oncol. 36(22): 2267-2280, 2018. [ Journal Article ]
- Nat Rev Clin Oncol. 15(1): 31-36, 2018. [ Journal Article ]
- Blood. 127(26): 3321-3330, 2016. [ Journal Article ]
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.J Clin Oncol. 34(10): 1112-1121, 2016. [ Journal Article ]
- Blood. 127(8): 965-970, 2016. [ Journal Article ]
Dr. Brudno received her Bachelor of Arts from Princeton University and her M.D. from the Emory University School of Medicine. While in medical school, she participated in the NIH Clinical Research Training Program (CRTP), during which she worked with Dr. Neal Young in the National Heart, Lung, and Blood Institute. She completed her medical residency in internal medicine at the Johns Hopkins University School of Medicine. She then completed fellowship training in medical oncology and hematology through the National Cancer Institute and the National Heart, Lung, and Blood Institute. After fellowship training, she joined the research group of Dr. James Kochenderfer in the Experimental Transplantation and Immunology Branch.
Dr. Brudno is board certified in internal medicine, hematology, and medical oncology.